Should I buy or sell Verrica Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VRCA shares. View VRCA analyst ratings or view top-rated stocks .

What is Verrica Pharmaceuticals' stock price target for 2024?

4 Wall Street research analysts have issued 12-month price targets for Verrica Pharmaceuticals' shares. Their VRCA share price targets range from $8.00 to $14.00. On average, they anticipate the company's share price to reach $11.25 in the next twelve months. This suggests a possible upside of 59.3% from the stock's current price. View analysts price targets for VRCA or view top-rated stocks among Wall Street analysts .

How have VRCA shares performed in 2024?

Verrica Pharmaceuticals' stock was trading at $7.32 at the beginning of the year. Since then, VRCA stock has decreased by 3.6% and is now trading at $7.06. View the best growth stocks for 2024 here .

When is Verrica Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VRCA earnings forecast .

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) issued its earnings results on Thursday, February, 29th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.01. The firm had revenue of $1.99 million for the quarter, compared to analysts' expectations of $1.10 million. Verrica Pharmaceuticals had a negative trailing twelve-month return on equity of 119.46% and a negative net margin of 1,307.47%.

What other stocks do shareholders of Verrica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA) , Matinas BioPharma (MTNB) , Novan (NOVN) , Zosano Pharma (ZSAN) , Bionano Genomics (BNGO) , CBL & Associates Properties (CBL) , Gran Tierra Energy (GTE) , Pennsylvania Real Estate Investment Trust (PEI) , Organigram (OGI) and Aeterna Zentaris (AEZS) .

When did Verrica Pharmaceuticals IPO?

Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VRCA

Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free VRCA Stock Alerts

$7.06

+0.06 (+0.86%)

(As of 04/17/2024 ET)

Compare

Today's Range: $6.93
▼
$7.14
50-Day Range: $4.74
▼
$7.19
52-Week Range: $2.86
▼
$7.76

Volume: 105,357 shs
Average Volume: 157,340 shs
Market Capitalization: $299.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.25

Get Verrica Pharmaceuticals alerts:

Verrica Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 59.3% Upside
$11.25 Price Target
Short Interest: Bearish
16.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.59) to ($0.63) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.85 out of 5 stars

Medical Sector

180th out of 913 stocks

Biotechnology Industry

9th out of 64 stocks

3.5

Analyst's Opinion

Consensus Rating
Verrica Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Verrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
16.52% of the float of Verrica Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Verrica Pharmaceuticals has a short interest ratio ("days to cover") of 28.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Verrica Pharmaceuticals has recently decreased by 5.00%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Verrica Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Verrica Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Verrica Pharmaceuticals has received a 75.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Verrica Pharmaceuticals is -0.67.

2.3

News and Social Media Coverage

News Sentiment
Verrica Pharmaceuticals has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
3 people have searched for VRCA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
5 people have added Verrica Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.50% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($1.59) to ($0.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Verrica Pharmaceuticals is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Verrica Pharmaceuticals is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Verrica Pharmaceuticals has a P/B Ratio of 15.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Verrica Pharmaceuticals Stock (NASDAQ:VRCA)

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

VRCA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VRCA Stock News Headlines

April 11, 2024 | americanbankingnews.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Given "Buy" Rating at Needham & Company LLC

April 4, 2024 | msn.com

Verrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare Conference

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 3, 2024 | finance.yahoo.com

Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss

April 2, 2024 | globenewswire.com

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

March 31, 2024 | msn.com

Verrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market Protection

March 28, 2024 | finanznachrichten.de

Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA

March 27, 2024 | msn.com

Verrica Pharma gains as FDA lists Ycanth in Orange Book

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 26, 2024 | markets.businessinsider.com

Verrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Facts

March 26, 2024 | globenewswire.com

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

March 3, 2024 | msn.com

Verrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside Chat

March 2, 2024 | finance.yahoo.com

Verrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line

March 2, 2024 | finance.yahoo.com

When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?

March 1, 2024 | finanznachrichten.de

Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

March 1, 2024 | markets.businessinsider.com

Verrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy Rating

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market Expansion

March 1, 2024 | finance.yahoo.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript

February 29, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market Acceptance

February 29, 2024 | finance.yahoo.com

Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results

February 29, 2024 | globenewswire.com

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

February 28, 2024 | benzinga.com

Earnings Outlook For Verrica Pharmaceuticals

February 27, 2024 | globenewswire.com

Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference

February 22, 2024 | finance.yahoo.com

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

February 22, 2024 | globenewswire.com

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

February 12, 2024 | msn.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Is Egging on Contrarian Options Traders

February 6, 2024 | finance.yahoo.com

7 Potential Short-Squeeze Stocks Poised for Rapid Gains

See More Headlines

Receive VRCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:VRCA
CUSIP: N/A
CIK: 1660334
Web: www.verrica.com
Phone: (434) 453-3300
Fax: N/A
Employees: 100
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.25
High Stock Price Target: $14.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +59.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-67,000,000.00
Net Margins: -1,307.47%
Pretax Margin: -1,307.47%
Return on Equity: -119.46%
Return on Assets: -70.35%

Debt

Debt-to-Equity Ratio: 2.22
Current Ratio: 4.55
Quick Ratio: 4.49

Sales & Book Value

Annual Sales: $5.12 million
Price / Sales: 58.49
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.47 per share
Price / Book: 15.02

Miscellaneous

Outstanding Shares: 42,420,000
Free Float: 24,815,000
Market Cap: $299.49 million
Optionable: Optionable
Beta: 1.88

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Ted White (Age 59)
President, CEO & Director
Comp: $772.77k
Mr. Joe Bonaccorso (Age 60)
Chief Commercial Officer
Comp: $550.37k
Dr. Gary Goldenberg M.D. (Age 47)
Chief Medical Officer
Comp: $553.03k
Mr. P. Terence Kohler
Chief Financial Officer
Mr. Christopher G. Hayes (Age 60)
Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel
Mr. Eugene Scavola
Executive Vice President of Technical Operations
Dr. Bradley J. Catalone MBA
Ph.D., Head of Drug Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VRCA Stock Analysis - Frequently Asked Questions

Should I buy or sell Verrica Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VRCA shares.
View VRCA analyst ratings or view top-rated stocks.
What is Verrica Pharmaceuticals' stock price target for 2024?: 4 Wall Street research analysts have issued 12-month price targets for Verrica Pharmaceuticals' shares. Their VRCA share price targets range from $8.00 to $14.00. On average, they anticipate the company's share price to reach $11.25 in the next twelve months. This suggests a possible upside of 59.3% from the stock's current price.
View analysts price targets for VRCA or view top-rated stocks among Wall Street analysts.
How have VRCA shares performed in 2024?: Verrica Pharmaceuticals' stock was trading at $7.32 at the beginning of the year. Since then, VRCA stock has decreased by 3.6% and is now trading at $7.06.
View the best growth stocks for 2024 here.
When is Verrica Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VRCA earnings forecast.

How were Verrica Pharmaceuticals' earnings last quarter?: Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) issued its earnings results on Thursday, February, 29th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.01. The firm had revenue of $1.99 million for the quarter, compared to analysts' expectations of $1.10 million. Verrica Pharmaceuticals had a negative trailing twelve-month return on equity of 119.46% and a negative net margin of 1,307.47%.
What other stocks do shareholders of Verrica Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Novan (NOVN), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI) and Aeterna Zentaris (AEZS).
When did Verrica Pharmaceuticals IPO?: Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.
How do I buy shares of Verrica Pharmaceuticals?: Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VRCA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis

Verrica Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Verrica Pharmaceuticals Stock (NASDAQ:VRCA)

VRCA Stock Price History

VRCA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VRCA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™